PG010 / PersonGen Biomedicine - LARVOL DELTA

A B7-H3-CAR-modified Vδ1 T cells showed potentanti-solid tumor potential (AACR 2024) - "UTAA06 exhibited extraordinary anticancer properties both in vitro and in vivo against solid tumors. Additionally, the outstanding manufacturing process of UTAA06 will facilitate the clinical application of this product."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Neuroblastoma • Oncology • Pancreatic Cancer • Solid Tumor • CD27 • CD276 • CXCR3 • CXCR6 • IL17A • IL2 • LAG3 • NKG2D • TNFRSF9

A phase I, open-label study of the novel B7-H3 targeted CAR-Vδ1T in patients with advanced solid tumours (ESMO 2025) - P1 | "Conclusions UTAA06, a first-in-class B7-H3-targeted CAR-Vδ1T therapy, demonstrates manageable safety and preliminary antitumor activity in heavily pretreated advanced solid tumor patients at doses up to 1×10ˆ9 cells. Ongoing evaluation will further characterize safety, pharmacokinetics, and efficacy in expanded cohorts."

Clinical • IO biomarker • Metastases • Oncology • Solid Tumor

The preclinical research results of Boshengji’s generic UCAR-Vδ1 T cell therapy for solid tumors were officially published in the AACR flagship journal [Google translation] (bydrug.pharmcube.com) - "It is worth emphasizing that the B7-H3-CAR-Vδ1T cell product is the first universal off-the-shelf CAR-Vδ1T cell drug developed by Boshengji that targets solid tumors, does not require gene editing, and is highly cost-effective. It is also the first reported B7-H3-CAR-γδT cell product developed based on Vδ1T cells targeting solid tumors in the world...CAR-T cell therapy, which has achieved great success in the clinical treatment of hematological tumors, is not ideal in the clinical treatment of solid tumors due to the complexity of solid tumors, such as tumor immunosuppressive microenvironment, CAR-T cell homing disorders, and tumor antigen heterogeneity."

Preclinical • Oncology • Solid Tumor